The design of prodrugs focuses on achieving higher concentrations of the active drug in tumor tissues, thereby sparing normal tissues from high exposure. This preferential activation reduces the risk of systemic toxicity and often allows for higher dosing of the chemotherapeutic agent, potentially improving therapeutic outcomes. By reducing off-target effects, prodrugs can also lead to better patient compliance and quality of life during treatment.
